Compare ORMP & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORMP | EARN |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 169.8M |
| IPO Year | 2010 | 2012 |
| Metric | ORMP | EARN |
|---|---|---|
| Price | $4.71 | $4.26 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 220.5K | ★ 348.0K |
| Earning Date | 05-14-2026 | 06-16-2026 |
| Dividend Yield | 6.51% | ★ 20.51% |
| EPS Growth | ★ 412.50 | N/A |
| EPS | ★ 2.76 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | $7.69 |
| Revenue Next Year | N/A | $19.57 |
| P/E Ratio | $1.69 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $2.09 | $4.25 |
| 52 Week High | $5.47 | $5.77 |
| Indicator | ORMP | EARN |
|---|---|---|
| Relative Strength Index (RSI) | 48.89 | 46.04 |
| Support Level | $3.91 | $4.29 |
| Resistance Level | $5.10 | $4.49 |
| Average True Range (ATR) | 0.24 | 0.06 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 8.43 | 23.81 |
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.